BioNxt Solutions Inc.
BioNxt Solutions Inc. engages in research, development, manufacture, and sale of next generation drug formulations and delivery systems in Austria, Germany, and Switzerland. The company provides BNT23001for the treatment of multiple sclerosis; BNT23002 for the treatment of myasthenia gravis; BNT24002, a sublingual thin film for the treatment of lupus nephritis; BNT24003 for the treatment of rheum… Read more
BioNxt Solutions Inc. (BNXTF) - Net Assets
Latest net assets as of September 2025: $-8.31 Million USD
Based on the latest financial reports, BioNxt Solutions Inc. (BNXTF) has net assets worth $-8.31 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.23 Million) and total liabilities ($9.54 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-8.31 Million |
| % of Total Assets | -677.85% |
| Annual Growth Rate | N/A |
| 5-Year Change | -296.26% |
| 10-Year Change | N/A |
| Growth Volatility | 134.78 |
BioNxt Solutions Inc. - Net Assets Trend (2018–2024)
This chart illustrates how BioNxt Solutions Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for BioNxt Solutions Inc. (2018–2024)
The table below shows the annual net assets of BioNxt Solutions Inc. from 2018 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-7.86 Million | -48.82% |
| 2023-12-31 | $-5.28 Million | -27.96% |
| 2022-12-31 | $-4.13 Million | -347.41% |
| 2021-12-31 | $1.67 Million | -58.34% |
| 2020-12-31 | $4.01 Million | -36.66% |
| 2019-12-31 | $6.32 Million | -18.53% |
| 2018-12-31 | $7.76 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to BioNxt Solutions Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 6382323600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $56.83 Million | % |
| Total Equity | $-7.86 Million | 100.00% |
BioNxt Solutions Inc. Competitors by Market Cap
The table below lists competitors of BioNxt Solutions Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
5paisa Capital Ltd
NSE:5PAISA
|
$34.50 Million |
|
PharmGen Science Inc
KO:004720
|
$34.50 Million |
|
Kron Telekomunikasyon Hizmetleri AS
IS:KRONT
|
$34.53 Million |
|
Shihlin Development Company Limited
TWO:5324
|
$34.54 Million |
|
Ditas Dogan Yedek Parca Imalat ve Teknik AS
IS:DITAS
|
$34.48 Million |
|
H&R GmbH & Co. KGaA
XETRA:2HRA
|
$34.48 Million |
|
Vittia Fertilizantes
SA:VITT3
|
$34.48 Million |
|
Trk Corp
TW:1432
|
$34.47 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BioNxt Solutions Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -5,282,662 to -7,861,460, a change of -2,578,798.
- Net loss of 5,311,505 reduced equity.
- New share issuances of 1,713,000 increased equity.
- Other factors increased equity by 1,019,707.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-5.31 Million | -67.56% |
| Share Issuances | $1.71 Million | +21.79% |
| Other Changes | $1.02 Million | +12.97% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares BioNxt Solutions Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $0.16 | $0.30 | x |
| 2019-12-31 | $0.13 | $0.30 | x |
| 2020-12-31 | $0.06 | $0.30 | x |
| 2021-12-31 | $0.02 | $0.30 | x |
| 2022-12-31 | $-0.05 | $0.30 | x |
| 2023-12-31 | $-0.05 | $0.30 | x |
| 2024-12-31 | $-0.07 | $0.30 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently BioNxt Solutions Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -19683.18%
- • Asset Turnover: 0.05x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-255.82%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -11.09% | 0.00% | 0.00x | 1.15x | $-1.64 Million |
| 2019 | -121.27% | -3684.77% | 0.02x | 1.37x | $-8.30 Million |
| 2020 | -421.65% | -4886.32% | 0.04x | 2.07x | $-17.29 Million |
| 2021 | -1236.76% | -7203.23% | 0.03x | 5.83x | $-20.80 Million |
| 2022 | 0.00% | -4160.84% | 0.18x | 0.00x | $-11.96 Million |
| 2023 | 0.00% | -2074.68% | 0.29x | 0.00x | $-7.19 Million |
| 2024 | 0.00% | -19683.18% | 0.05x | 0.00x | $-4.53 Million |
Industry Comparison
This section compares BioNxt Solutions Inc.'s net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BioNxt Solutions Inc. (BNXTF) | $-8.31 Million | -11.09% | N/A | $34.49 Million |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |